STAT

OCTOBER 17, 2022

Research at Boston University that involved testing a lab-made hybrid version of the SARS-CoV-2 virus is garnering heated headlines alleging the scientists involved could have unleashed a new pathogen. There is no evidence the work, performed under biosecurity level 3 precautions in BU’s National Emerging Infectious Diseases Laboratories, was conducted improperly or unsafely.

364

364

PharmaVoice

OCTOBER 17, 2022

Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

246

246

Pharmacy Is Right For Me

OCTOBER 21, 2022

There are so many different types of careers within the field of pharmacy—from research and drug development to pharmacy informatics! To highlight some of the more unique career settings in the industry, we’re introducing a new page on our website— Novel Pharmacy Practice Settings —where you can explore these unique career pathways. In addition to learning more about unique pathways on our new webpage, we’ll also be featuring pharmacists who work in these unique settings on our blog.

Hospitals 130

Hospitals Labelling Vaccines Drug Development 130

European Pharmaceutical Review

OCTOBER 20, 2022

In recent years there has been significant development within the cell therapy field, as chimeric antigen receptor (CAR) T-cell therapy demonstrated an ability to transform the treatment of patients with haematological malignancies. Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?

Immunity 124

Immunity Immunization Drug Development 124

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

OCTOBER 17, 2022

Before the Covid-19 pandemic emerged, influenza trackers would begin reading tea leaves around this time of the year, looking for signs of whether there would be an early start to the flu season in the northern hemisphere and which of the various flu viruses might be responsible for the most cases over the coming winter. Flu transmission has been low since the start of the pandemic , but an odd spurt of activity in April, May, and even early June of 2022 — which coincided with the onset o

348

348

PharmaVoice

OCTOBER 20, 2022

The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.

264

264

European Pharmaceutical Review

OCTOBER 17, 2022

Novartis announced that The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Pluvicto ® radioligand therapy for treatment of patients with prostate cancer. Pluvicto combines a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope (in this case lutetium-177).

Chemotherapy 119

Chemotherapy Compounding 119

STAT

OCTOBER 16, 2022

In an unusual step, the European Public Prosecutor’s Office (EPPO) confirmed it has opened an investigation into the Covid-19 contracts signed by the European Union, a move that comes shortly after numerous members of the European Parliament harshly criticized a lack of transparency surrounding an agreement with Pfizer. The EPPO is an independent public prosecution office that is responsible for investigating, prosecuting, and bringing to judgment crimes such as fraud, money laundering an

Vaccines 346

Vaccines 346

PharmaVoice

OCTOBER 21, 2022

C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

279

279

Pharmaceutical Technology

OCTOBER 19, 2022

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 for each share in cash. The deal comprises an acquisition value of $12.50 for each share in cash payable at closing along with one non-tradeable contingent value right per share (CVR) of up to another $3 in cash.

119

119

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharma Times

OCTOBER 17, 2022

Demonstrators will demand hundreds of millions of pounds ‘missing’ from ME research

149

149

STAT

OCTOBER 16, 2022

When it comes to eradicating infectious diseases, there can be no half measures: it’s an all-or-nothing proposition. For more than three decades, eradicating polio — removing it from the face of the earth — has been the sole mission of the Global Polio Eradication Initiative (GPEI). But now, after helping drive down the global number of cases by 99.9%, and with the wild poliovirus only endemic in just two countries, this incredible initiative is in danger of becoming a victi

Vaccines 316

Vaccines 316

PharmaVoice

OCTOBER 20, 2022

Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.

Drug Development 246

Drug Development 246

pharmaphorum

OCTOBER 20, 2022

And the LIVE coverage continues as we head into Day Two… This day is set to hold even more points of interest, with the demonstration ‘CX innovation: building experiences that work for customers’ (moderated by Healthware Group’s global head of digital strategy and customer engagement Yannick Valenti), as well as the masterclass ‘How to maximise learning science to affect behaviour change’ with Meducate Global’s president, Lawrence Sherman, and MD of Healthware MedComms & SWM, Francis M

112

112

Pharma Times

OCTOBER 18, 2022

Therapy is based on ACD856's indicative disease modifying effects against the condition

153

153

STAT

OCTOBER 19, 2022

Since the world began confronting a global outbreak of monkeypox in the spring, the scientific community has had plenty of reasons to rue the fact that for decades this virus has been understudied. Here’s another one: Because of that oversight, doctors treating people who have been infected with monkeypox can’t answer with certainty whether some of them will face any long-term health consequences, referred to as sequelae in the field of medicine.

313

313

PharmaVoice

OCTOBER 18, 2022

Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.

Drug Development 279

Drug Development 279

pharmaphorum

OCTOBER 17, 2022

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. Elinzanetant is already being tested in the OASIS trials for VMS associated with menopause – an indication in which Bayer is in a head-to-head race with Astellas and its fezolinetant drug candidate – and breast cancer could represent a sizeable additional patient population for the drug.

106

106

Pharma Times

OCTOBER 19, 2022

Therapy treats refractory chronic immune thrombocytopenia and is available across UK

Immunity 144

Immunity Immunization 144

STAT

OCTOBER 19, 2022

Early in the Covid-19 pandemic, the leaders of wealthy countries pledged to respond with “global solidarity.” But when vaccines to prevent the disease were developed, those same leaders pushed low and middle-income countries to the back of the queue, outbidding poorer countries, as well as COVAX, a worldwide initiative developed to achieve equitable vaccine access, to secure vaccines for themselves.

Vaccines 299

Vaccines Pharmaceutical Companies Pharmaceutical Companies 299

PharmaVoice

OCTOBER 19, 2022

Is the industry ready for a biologic discovery revolution? Charlotte Deane, chief scientist of biologics AI at Exscientia, thinks so.

246

246

EMCrit Project

OCTOBER 21, 2022

Every Resus doc should be able to crash a patient on to APRV for lung rescue. EMCrit Project by Scott Weingart, MD FCCM.

128

128

Pharma Times

OCTOBER 18, 2022

First treatment in 30 years to improve second-line treatment of DLBCL

153

153

STAT

OCTOBER 18, 2022

A fourth-year medical student, Tema, faced an abrupt interruption to her education earlier this year. A state law banning abortion after six weeks went into effect hours after the U.S. Supreme Court overturned Roe v. Wade, and two days later, the clinic where her school provided first-hand abortion experience shut down. “I’d do my patients a great disservice if I’m not trained in abortion,” said Tema, who is planning to become a family planning doctor, and asked that

Medical Schools 295

Medical Schools 295

PharmaVoice

OCTOBER 18, 2022

Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.

Drug Pricing 246

Drug Pricing 246

pharmaphorum

OCTOBER 19, 2022

Frontiers Health 2022 in Milan is LIVE! Opening Day One will be Healthware Group’s CEO and founder Roberto Ascione and WTF Health’s founder and host Jessica DaMassa. The day’s keynote addresses will include ‘The H is for humanity’ by MD of Taliossa Tony Estrella and founder and trustee of Rachel’s House Lynna Chandra, as well as ‘Creative disruption in delivering novel VR solutions in pain: evidence, teamwork, and delivery’ by Christopher Eccleston, professor of medical psychology at the U

102

102

European Pharmaceutical Review

OCTOBER 18, 2022

Kite announced that the European Commission (EC) has approved the use of cell therapy Yescarta ® for treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), who relapse within 12 months or are refractory to, first-line chemoimmunotherapy. The approval is based on results from the Phase III ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus standard of care (SOC) in this patient population.

Chemotherapy 102

Chemotherapy 102

STAT

OCTOBER 18, 2022

The director of a Boston University laboratory that conducted potentially controversial research on the viruses that cause Covid-19 said his institution didn’t clear the work with the National Institutes of Health because it wasn’t funded by the federal agency. Ronald Corley said the research, which was designed to explore what makes some SARS-CoV-2 viruses more or less pathogenic, was funded with money from the university itself.

290

290

PharmaVoice

OCTOBER 19, 2022

Major recent trial flops and what they mean for companies, patients and the industry.

299

299

pharmaphorum

OCTOBER 21, 2022

Young adults with depression have been treated effectively with a cognitive behavioural therapy (CBT) course – delivered via text message – in a pilot study conducted by researchers in the US. The trial looked at a four-week CBT course adapted from a face-to-face programme to work via text messages, followed by a four-week follow-up period, in around 100 young adults in the US with at least one symptom of moderate depression and no recent history of antidepressant therapy.

101

101

European Pharmaceutical Review

OCTOBER 20, 2022

Apogenix , a biopharmaceutical company developing next generation immunotherapeutics, announced that asunercept showed statistically significant benefits for hospitalised COVID-19 patients in the ASUNCTIS trial. Apogenix’s lead immunotherapy candidate, asunercept is a fully human fusion protein, consisting of the CD95 receptor and an IgG1 antibody. It is being developed for the treatment of solid tumours, haematological malignancies and viral infections such as COVID-19.

Immunity 101

Immunity Immunization 101

STAT

OCTOBER 17, 2022

The University of Pennsylvania’s Division of Renal-Electrolyte and Hypertension recently made a quiet update to its history web page : it removed all references to its former co-chief, Dr. Stanley Goldfarb. For several years, Goldfarb has been a vocal critic of considering social determinants of health, racism, and anything else he considers too “woke” in medical education or health care at large.

284

284

PharmaVoice

OCTOBER 17, 2022

Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.

246

246

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed.

Immunity 102

Immunity Immunization Drug Development 102

The Guardian - Pharmaceutical Industry

OCTOBER 16, 2022

U?ur ?ahin and Özlem Türeci say mRNA Covid vaccine technology could be repurposed to help destroy cancer cells Vaccines that target cancer could be available before the end of the decade, according to the husband and wife team behind one of the most successful Covid vaccines of the pandemic. U?ur ?ahin and Özlem Türeci, who co-founded BioNTech, the German firm that partnered with Pfizer to manufacture a revolutionary mRNA Covid vaccine, said they had made breakthroughs that fuelled their optimis

Vaccines 100

Vaccines 100